CureVac, NL0015436031

CureVac, NL0015436031

18.11.2021 - 11:46:31

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at

Language: English Company: CureVac Friedrich-Miescher-Str. 15 72076 T?bingen

Germany EQS News ID: 1250113 ? End of News DGAP News Service